Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

| Name of entity | |
|-------------------------|--|
| Phylogica Limited (PYC) | |
| | |
| ABN | |
| 48 098 391 961 | |

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

†Class of *securities issued or to be issued

Fully paid ordinary shares issued under a pro-rata non-renounceable entitlement offer on the basis of 1 new share for every 5 shares held by eligible shareholders in **PYC** on the applicable record date at an issue price of \$0.055 per share (**Entitlement Offer**).

Number of *securities issued or to be issued (if known) or maximum number which may be issued PYC proposes to issue approximately 488,571,332 new shares pursuant to the Entitlement Offer announced to ASX on 31 October 2019

The final number of shares to be issued under the Entitlement Offer is still to be finalised, and will be subject to holding reconciliation and rounding.

04/03/2013 Doc ID 678597363/v1

⁺ See chapter 19 for defined terms.

3 Principal terms of the Fully paid ordinary shares to rank equally +securities (e.g. if options, with other fully paid ordinary shares on exercise price and expiry date; issue. if partly paid +securities, the amount outstanding and due for payment; dates if +convertible securities, the conversion price and dates for conversion) Do the +securities rank equally Yes. in all respects from the +issue date with an existing +class of quoted +securities? If the additional +securities do not rank equally, please state: • the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend. distribution interest payment 5 Issue price or consideration \$0.055 per share. Purpose of the issue 6 Please refer to the ASX announcement on (If issued as consideration for 31 October 2019 for the purpose of the the acquisition of assets, clearly issue. identify those assets) Is the entity an +eligible entity 6a No. that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b -6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i The date the security holder N/A 6b resolution under rule 7.1A was

passed

| 6c | Number of *securities issued without security holder approval under rule 7.1 | N/A |
|----|---|--|
| 6d | Number of *securities issued with security holder approval under rule 7.1A | N/A |
| 6e | Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) | N/A |
| 6f | Number of *securities issued under an exception in rule 7.2 | N/A |
| 6g | If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation. | N/A |
| 6h | If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements | N/A |
| 6i | Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A — complete Annexure 1 and release to ASX Market Announcements | Listing Rule 7.1 - 366,428,499. |
| 7 | *Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. | The proposed issue and allotment date for the institutional component of the Entitlement Offer is 7 November 2019 and for the retail component of the Entitlement Offer is 25 November 2019. |

Cross reference: item 33 of Appendix 3B.

⁺ See chapter 19 for defined terms.

8 Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)

| Number | +Class |
|------------------------|---------------------|
| Approximately | Fully paid ordinary |
| 2,931,427,990 shares | shares |
| (after the Entitlement | |
| Offer) | |
| | |
| | |
| | |

9 Number and +class of all *securities not quoted on ASX (including the +securities in section 2 if applicable)

| Number | +Class |
|------------|--|
| 10,000,000 | Unlisted Options expiring 30/05/2020, exercise price \$0.06 |
| 10,000,000 | Unlisted Options expiring 16/11/2021, exercise price \$0.039 |

10 Dividend policy (in the case of a N/A trust, distribution policy) on the increased capital (interests)

Part 2 - Pro rata issue

11 Is security holder approval required?

No.

- 12 Is the issue renounceable or non-renounceable?
- Non-renounceable.
- 13 Ratio in which the +securities will be offered
- 1 new share for every 5 shares held by eligible shareholders in PYC on the record date.
- 14 *Class of *securities to which the offer relates
- Fully paid ordinary shares in PYC.
- 15 *Record date to determine entitlements
- 5.00pm (WST) on 4 November 2019.
- Will 16 different holdings on registers (or subregisters) be aggregated for calculating entitlements?
- N/A
- 17 Policy for deciding entitlements in relation to fractions

Fractional entitlements will be rounded to the next higher whole number of new shares.

18 Names of countries in which the All countries other than Australia and New entity has security holders who Zealand. will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. 19 Closing date for receipt of For the institutional component of the acceptances or renunciations Entitlement Offer, 7 November 2019. For the retail component of the Entitlement Offer, 5.00pm (WST) on 18 November 2019. 20 Names of any underwriters Australian Land Pty Ltd ABN 55 612 406 550. 21 Amount of any underwriting fee An underwriting fee of 5.0% of the total or commission proceeds of the Entitlement Offer (other than money raised by the underwriter taking up its Entitlement under the institutional component of the Entitlement Offer). 22 Names of any brokers to the N/A issue 23 Fee or commission payable to N/A the broker to the issue 24 Amount of any handling fee N/A payable to brokers who lodge acceptances or renunciations on behalf of security holders 25 If the issue is contingent on N/A security holders' approval, the date of the meeting No prospectus is being prepared. A Retail 26 Date entitlement and acceptance form and offer Entitlement Offer Booklet, and entitlement documents will be sent to and acceptance form will be sent to persons entitled eligible PYC retail securityholders on or around 7 November 2019.

⁺ See chapter 19 for defined terms.

| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | N/A |
|-----|---|--|
| 28 | Date rights trading will begin (if applicable) | N/A |
| 29 | Date rights trading will end (if applicable) | N/A |
| 30 | How do security holders sell their entitlements <i>in full</i> through a broker? | N/A |
| 31 | How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | N/A |
| 32 | How do security holders dispose of their entitlements (except by sale through a broker)? | N/A |
| 33 | +Issue date | Allotment and normal trading on ASX of new shares issued under the institutional component of the Entitlement Offer - 4 November 2019. |
| | | Allotment of new shares issued under the retail component of the Entitlement Offer - 25 November 2019. |
| | : 3 - Quotation of sec ed only complete this section if you are | |
| 34 | Type of *securities (tick one) | |
| (a) | *Securities described in Part 1 | |
| (b) | | end of the escrowed period, partly paid securities that become fully paid, when restriction ends, securities issued on expiry or conversion of |

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

| Tick to docum | o indicate you are providing the information or nents |
|------------------|--|
| 35 | If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders |
| 36 | If the *securities are *equity securities, a distribution schedule of the additiona *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over |
| 37 | A copy of any trust deed for the additional *securities |
| Enti | ties that have ticked box 34(b) |
| 38 | Number of *securities for which *quotation is sought |
| 39 | ⁺ Class of ⁺ securities for which quotation is sought |
| 40 | Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? |
| | If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment |

04/03/2013 Doc ID 678597363/v1

⁺ See chapter 19 for defined terms.

| 41 | Reason for request for quotation now | |
|----|---|--|
| | Example: In the case of restricted securities, end of restriction period | |
| | (if issued upon conversion of another *security, clearly identify that other *security) | |

42 Number and *class of all *securities quoted on ASX (including the *securities in clause 38)

| Number | †Class |
|--------|--------|
| | |
| | |
| | |
| | |
| | |
| | |

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

(Director/Company secretary)

Print name: Kevin Hart

== == == ==

Date: 31 October 2019

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

| Rule 7.1 – Issues exceeding 15% of capital | |
|---|---|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated | |
| Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue | 2,138,856,650 |
| Add the following: | |
| Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 | 21.09.18 Placement 146,166,674 ordinary Shares ratified by shareholders at the |
| Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval | Annual General Meeting held on 16 November 2018. 30.11.2018 Placement 157,833,334 ordinary |
| Number of partly paid *ordinary securities that became fully paid in that 12 month period | shares as noted in the Appendix 3B to which this form is annexed. |
| Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | |
| Subtract the number of fully paid *ordinary securities cancelled during that 12 month period | nil. |
| "A" | 2,442,856,658 |

Step 2: Calculate 15% of "A"

⁺ See chapter 19 for defined terms.

| "B" | 0.15 |
|---|--|
| | [Note: this value cannot be changed] |
| Multiply "A" by 0.15 | 366,428,499 |
| Step 3: Calculate "C", the amount that has already been used | of placement capacity under rule 7.1 |
| Insert number of *equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued: | - |
| Under an exception in rule 7.2 | |
| Under rule 7.1A | |
| With security holder approval under rule 7.1 or rule 7.4 | |
| Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | |
| "C" | - |
| Step 4: Subtract "C" from ["A" x "l placement capacity under rule 7.1 | B"] to calculate remaining |
| "A" x 0.15 | 366,428,499 |
| Note: number must be same as shown in Step 2 | |
| Subtract "C" | - |
| Note: number must be same as shown in Step 3 | |
| <i>Total</i> ["A" x 0.15] – "C" | 366,428,499[Note: this is the remaining placement capacity under rule 7.1] |

Part 2

| Rule 7.1A – Additional placement capacity for eligible entities | | |
|--|------------------------------------|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated | | |
| "A" | N/A | |
| Note: number must be same as shown in Step 1 of Part 1 | | |
| Step 2: Calculate 10% of "A" | | |
| "D" | 0.10 | |
| | Note: this value cannot be changed | |
| Multiply "A" by 0.10 | | |
| Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used | | |
| Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A | | |
| Notes: • This applies to equity securities – not just ordinary securities • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained • It may be useful to set out issues of securities on different dates as separate line items | N/A | |
| "E" | N/A | |

04/03/2013 Doc ID 678597363/v1

⁺ See chapter 19 for defined terms.

| Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A | |
|---|--|
| "A" x 0.10 | |
| Note: number must be same as shown in Step 2 | |
| Subtract "E" | |
| Note: number must be same as shown in Step 3 | |
| Total ["A" x 0.10] – "E" | N/A |
| | Note: this is the remaining placement capacity under rule 7.1A |